This clinical trial failed to achieve the primary endpoint and it failed to prove the efficacy of adding avelumab immunotherapy to platinum‐based chemotherapy in the neoadjuvant treatment of patients with nonsmall cell lung cancer irrespective to the tumor PD‐L1 expression. This evidence concerns the gene CD274 and neoplasm.